Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study

Leuk Lymphoma. 2020 Feb;61(2):494-496. doi: 10.1080/10428194.2019.1672054. Epub 2019 Oct 3.

Affiliations

¹ Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
² 4th Department of Internal Medicine Hematology, Charles University Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic.
³ Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
⁴ Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.

PMID: 31580157
DOI: 10.1080/10428194.2019.1672054

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents*
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / etiology
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Imatinib Mesylate / adverse effects
Lipids
Prospective Studies
Protein Kinase Inhibitors
Pyrimidines
Risk Factors

Substances

Antineoplastic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
nilotinib